Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-021-01449-9

Leif Erik Sander. “1/6 Our Study Comparing Reactogenicity & Immunogenicity of Homologous (2xBNT/Pfizer) vs Heterologous (AZ/ChAdOx +BNT) Vaccination Is Available Https://Medrxiv.Org/Content/10.1101/2021.05.19.21257334v2 Great Team Effort @vmcorman #FlorianKurth #DavidHillus #TatjanaSchwarz #PinkusToberLau et al. @ChariteBerlin 🧵 Https://T.Co/4zXfY4rV9c.” Tweet. @Sander_Lab (blog), June 2, 2021. https://twitter.com/Sander_Lab/status/1400178343123853321.